Building Health Sovereignty
Local pharmaceutical manufacturing has evolved into a strategic national priority, given its direct implications for public health security, economic resilience, and long-term competitiveness. Countries that rely heavily on imported medicines are exposed to supply chain disruptions, currency volatility, and geopolitical tensions that can compromise access to essential treatments, such as the Iran-Israel escalation and its spillover effects on regional stability and supply routes. Expanding domestic production reduces these vulnerabilities by shortening supply chains, strengthening healthcare system responsiveness, and anchoring greater value within national economies. Pharmaceutical localization has therefore emerged as a central pillar of health security and strategic autonomy across the Middle East.
In Saudi Arabia, pharmaceutical manufacturing is embedded within Vision 2030 as a component of economic diversification and industrial expansion. Strengthening domestic capacity, attracting advanced technologies, fostering global partnerships, and increasing the share of locally produced medicines collectively reinforce health security while accelerating the development of non-oil industries.
In Egypt, pharmaceutical expansion also aligns with Egypt Vision 2030, emphasizing industrial deepening, export growth, and economic diversification. The strategic ambition extends beyond self-sufficiency toward positioning Egypt as a regional manufacturing and export hub, with a gradual shift from high-volume generics toward more advanced segments such as biologics and innovative therapies.
Across both markets, localization delivers multidimensional benefits:
Strengthening healthcare stability
Supporting skilled employment
Attracting investment
Enhancing preparedness for both routine healthcare demand and large-scale emergencies
1-Pharmaceutical Industry Landscape
Two Markets Converging Toward Localisation.
The pharmaceutical sector in Egypt and Saudi Arabia reflect distinct starting points yet increasingly converging
trajectories. Both operate large and growing healthcare markets, but they differ in industrial maturity, value-chain
integration, and export positioning. Egypt represents a long-established production base characterized by high
domestic self-sufficiency and expanding exports. Saudi Arabia, by contrast, is a high-value consumption market
undergoing structural transformation under Vision 2030, with localization accelerating as part of a broader industrial
strategy.
2-Policy as a Catalyst
The State-Led Push for Localization.
In both Egypt and Saudi Arabia, pharmaceutical localization reflects deliberate and sustained national policy choices.
Governments increasingly view the sector as strategically critical for reducing import dependence, strengthening
resilience, and integrating into regional and global value chains. While their industrial foundations differ, both countries have embedded pharmaceutical manufacturing within long-term economic transformation agendas.
